文献速递血栓与止血

肥胖患者使用直接口服抗凝药治疗和预防静脉血栓栓塞:ISTH SSC抗凝控制小组委员会更新建议

Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.
PubMed 文献 · J Thromb Haemost · 2021-07-14

该更新建议由ISTH SSC抗凝控制小组委员会制定,综述了DOACs在肥胖患者VTE治疗和预防中的3期、4期研究、荟萃分析及药代动力学研究,并回顾减重手术后DOACs数据,给出更新指导建议。

要点

  • 肥胖患者使用DOACs治疗和预防VTE仍存在不确定,需参考更新建议。
  • 综述涵盖3期、4期、荟萃分析及药代/药效研究。
  • 减重手术后DOACs使用数据亦被纳入评估。

核心结论

  • DOACs在肥胖患者中治疗和预防VTE的疗效与安全性仍存在不确定性。

研究设计与样本

  • 由ISTH SSC抗凝控制小组委员会制定,综述3期、4期研究、荟萃分析及药代动力学和药效学研究。

临床怎么用

  • 为肥胖患者VTE治疗和预防及减重手术后DOACs使用提供更新指导建议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although direct-acting oral anticoagulants (DOACs) have widespread first-line use for treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding their efficacy and safety in patients with obesity. We reviewed available data for use of DOACs for VTE treatment and prevention in patients with obesity, including phase 3, phase 4, meta-analyses, and pharmacokinetic and pharmacodynamics studies. In addition, we reviewed available data regarding DOACs in bariatric surgery. We provide updated guidance recommendations on using DOACs in patients with obesity for treatment and prevention of VTE, as well as following bariatric surgery.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Martin KA, Beyer-Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021. PMID: 34259389. doi:10.1111/jth.15358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。